AbbVie (XSWX:ABBV) Long-Term Debt: CHF50,806 Mil (As of Mar. 2026)


XSWX:ABBV AbbVie Inc XSWX:ABBV
65 GF Score
Price CHF206.75
GF Value CHF167.66
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Long-Term Debt?

AbbVie XSWX:ABBV 65 Long-Term Debt is CHF50,806 Mil as of Mar. 2026. GuruFocus rates XSWX:ABBV with a GF Score™ of 65/100 and a GF Value™ of CHF167.66 (Modestly Overvalued). The stock has 4 warning signs investors should review.

AbbVie's Long-Term Debt for the quarter that ended in Mar. 2026 was CHF50,806 Mil.

AbbVie's quarterly Long-Term Debt declined from Sep. 2025 (CHF50,131 Mil) to Dec. 2025 (CHF46,970 Mil) but then increased from Dec. 2025 (CHF46,970 Mil) to Mar. 2026 (CHF50,806 Mil).

AbbVie's annual Long-Term Debt increased from Dec. 2023 (CHF45,137 Mil) to Dec. 2024 (CHF53,799 Mil) but then declined from Dec. 2024 (CHF53,799 Mil) to Dec. 2025 (CHF46,970 Mil).

AbbVie  (XSWX:ABBV) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

AbbVie Long-Term Debt Related Terms

AbbVie Long-Term Debt Historical Data

* Premium members only.

The historical data trend for AbbVie's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Long-Term Debt Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59,118.07 55,090.17 45,137.37 53,799.14 46,970.08

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57,016.06 51,198.26 50,131.21 46,970.08 50,806.04
XSWX:ABBV
65GF Score
AbbVie Inc XSWX:ABBV
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of CHF50,806 Mil mean?
AbbVie (XSWX:ABBV) has a Long-Term Debt of CHF50,806 Mil as of Mar. 2026.
Is AbbVie's Long-Term Debt too high?
AbbVie's current Long-Term Debt is CHF50,806 Mil. Overall, AbbVie has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Long-Term Debt compare to MRK and JNJ?
AbbVie's Long-Term Debt of CHF50,806 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. AbbVie's current Long-Term Debt is CHF50,806 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF167.66, compared to a current price of CHF206.75 — trading 23.3% above its estimated fair value. The current Long-Term Debt is CHF50,806 Mil. AbbVie's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current Long-Term Debt is CHF50,806 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (XSWX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of CHF206.75 is trading 23.3% above its estimated GF Value™ of CHF167.66. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for XSWX:ABBV:

  • Long-Term Debt: CHF50,806 Mil
  • GF Value™: CHF167.66 vs. price of CHF206.75 (23.3% above fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
65GF Score

Get the complete analysis for XSWX:ABBV

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF206.75
Price
CHF167.66
GF Value